FGFR inhibition augments anti–PD-1 efficacy in murine FGFR3-mutant bladder cancer by abrogating immunosuppression is a research paper published in Journal of Clinical Investigation (2024). On theSindex it has a DataRank of 0.520. It has been cited 31 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.520
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →NCI NIH HHS
Grant: T32 CA196589
Uehara Memorial Foundation
Grant: NA
NCI NIH HHS
Grant: P30 CA016086
KAKENHI
Grant: 21K20814
National Cancer Institute
Grant: R01-CA241810
University of North Carolina at Chapel Hill
Grant: UCRF
KAKENHI
Grant: 23K14628
NCI NIH HHS
Grant: R01 CA241810
National Institutes of Health
Grant: 3R01CA241810-04S1
In vivo Assessment of Chemotherapy Remodeling of the Bladder Cancer Immune Microenvironment
National Institutes of Health
Grant: 3P30CA016086-42S2
Cancer Center Support Grant
FWCI
13.16
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals